Cipla, a prominent Indian pharmaceutical company, announced that it has entered into a licensing agreement with Novartis Pharma AG (Switzerland) to produce and market the Galvus range, which is used in the treatment of type 2 diabetes, effective from January 1, 2026.
Buy Prime Test Series for all Banking, SSC, Insurance & other exams
According to the regulatory filing, Cipla has signed a perpetual license agreement to manufacture and market Galvus and Galvus combination brands. The drug firm believes that this partnership will enhance its standing in the diabetes category and reinforce its position as one of the major players in the Indian market. The agreement is contingent upon the fulfillment of certain preconditions, as stated by Cipla. The Galvus brand is a prominent name in the Dipeptidyl Peptidase-4 (DPP4) space and a major player in the oral diabetic medication category, according to the drug firm. On the Bombay Stock Exchange (BSE), Cipla’s shares rose by 1.02 percent to close at Rs 901.85 apiece.
You may also read this:
IIT-Bombay and UIDAI join hands to develop touchless biometric system
Welcome to the November 2025 Edition of the Affairs PDF – your all-inclusive monthly guide to…
The Reserve Bank of India (RBI) recently announced two major liquidity measures, a ₹1 trillion…
The ocean is full of amazing and mysterious creatures, many of which are rarely seen…
Russian President Vladimir Putin’s 2025 state visit to India marked a major diplomatic milestone, reviving…
In a major boost to Digital India, the Ministry of Electronics and Information Technology (MEITY)…
In an age where technology and finance intersect at lightning speed, Luana Lopes Lara, a…